COPD clinical trials in Louisiana
9 studies for COPD are looking for participants at sites in Louisiana.
Cities in Louisiana
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Southern Clinical Research - Zachary- Site Number : 8400113, Zachary
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Care Access - Shreveport - Youree Drive- Site Number : 8400007, Shreveport
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
- GSK Investigational Site, Lake Charles
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 9, 2026 · NCT07780669A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Zachary
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 9, 2026 · NCT07082738A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Southern Clinical Research, LLC, Zachary
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Lafayette
- Research Site, Monroe
- Research Site, Zachary
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966STRIVE Post-Market Registry Study
- LSU Health Shreveport, Shreveport
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lake Charles
- GSK Investigational Site, Shreveport
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Baton Rouge
- GSK Investigational Site, Lafayette
- GSK Investigational Site, Shreveport
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.